Free Trial
NASDAQ:CTOR

Citius Oncology (CTOR) Stock Price, News & Analysis

Citius Oncology logo
$0.91 0.00 (0.00%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$0.91 0.00 (0.00%)
As of 05/23/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Citius Oncology Stock (NASDAQ:CTOR)

Key Stats

Today's Range
$0.86
$0.91
50-Day Range
$0.61
$0.93
52-Week Range
$0.55
$4.42
Volume
13,909 shs
Average Volume
1.09 million shs
Market Capitalization
$65.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
Consensus Rating
Hold

Company Overview

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Receive CTOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Citius Oncology and its competitors with MarketBeat's FREE daily newsletter.

CTOR Stock News Headlines

The Hidden Energy Source Backed by Billionaires
Why Billionaires Have Set Their Sights on the Utah Desert Something strange is happening near the Wah Wah Mountains in Utah. Bezos, Buffett, and Gates are getting involved. But few Americans know why this remote patch of land is suddenly worth billions. One of our own insiders even filed a FOIA request in Washington to get to get the truth.
See More Headlines

CTOR Stock Analysis - Frequently Asked Questions

Citius Oncology's stock was trading at $1.15 at the start of the year. Since then, CTOR stock has decreased by 20.9% and is now trading at $0.91.
View the best growth stocks for 2025 here
.

Citius Oncology, Inc. (NASDAQ:CTOR) issued its quarterly earnings results on Wednesday, May, 14th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.02.

Shares of CTOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Oncology investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Advanced Micro Devices (AMD), Broadcom (AVGO), Confluent (CFLT), Genius Sports (GENI) and Intel (INTC).

Company Calendar

Last Earnings
5/14/2025
Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CTOR
Previous Symbol
NASDAQ:CTOR
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+229.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.22) per share
Price / Book
-4.14

Miscellaneous

Free Float
55,167,000
Market Cap
$65.11 million
Optionable
N/A
Beta
-0.17
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CTOR) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners